| Literature DB >> 30615702 |
Kelly Aubertin1,2, Joannie Desroches3, Michael Jermyn3,4, Vincent Quoc Trinh1,2,5,6, Fred Saad1,2,7,8, Dominique Trudel1,2,5,6, Frédéric Leblond1,3.
Abstract
For prostate cancer (PCa) patients, radical prostatectomy (complete removal of the prostate) is the only curative surgical option. To date, there is no clinical technique allowing for real-time assessment of surgical margins to minimize the extent of residual cancer. Here, we present a tissue interrogation technique using a dual excitation wavelength Raman spectroscopy system capable of sequentially acquiring fingerprint (FP) and high wavenumber (HWN) Raman spectra. Results demonstrate the ability of the system to detect PCa in post-prostatectomy specimens. In total, 477 Raman spectra were collected from 18 human prostate slices. Each area measured with Raman spectroscopy was characterized as either normal or cancer based on histopathological analyses, and each spectrum was classified based on supervised learning using support vector machines (SVMs). Based on receiver operating characteristic (ROC) analysis, FP (area under the curve [AUC] = 0.89) had slightly superior cancer detection capabilities compared with HWN (AUC = 0.86). Optimal performance resulted from combining the spectral information from FP and HWN (AUC = 0.91), suggesting that the use of these two spectral regions may provide complementary molecular information for PCa detection. The use of leave-one-(spectrum)-out (LOO) or leave-one-patient-out (LOPO) cross-validation produced similar classification results when combining FP with HWN. Our findings suggest that the application of machine learning using multiple data points from the same patient does not result in biases necessarily impacting the reliability of the classification models.Entities:
Keywords: (170.3880) Medical and biological imaging; (170.4580) Optical diagnostics for medicine; (170.5660) Raman spectroscopy; (170.6935) Tissue characterization
Year: 2018 PMID: 30615702 PMCID: PMC6157766 DOI: 10.1364/BOE.9.004294
Source DB: PubMed Journal: Biomed Opt Express ISSN: 2156-7085 Impact factor: 3.732
Fig. 1(a) Fresh human prostate slice on which measured areas were labelled using India ink and identified with blue circles. Scale bar = 1 cm. (b) Schematic depiction of the multi-wavelength Raman spectroscopy system. Fingerprint and high wavenumber Raman spectra are acquired following excitations at 785 nm (near infra-red [NIR]) and 671 nm, respectively.
Fig. 2Fingerprint (490-1660 cm−1) and high wavenumber (2800-3050 cm−1) average Raman spectra for normal (N = 393) and cancer (N = 84) prostatic tissues. The arrows identify prominent Raman peaks for which the results of univariate statistical tests are identified as follows: *** for p<0.001, ** for p<0.01, and * for p<0.05.
Univariate statistical analyses between normal and cancer prostatic tissues for prominent Raman peaks identified by arrows in Fig. 2. *** corresponds to p<0,001, ** to p<0,01 and * p<0,05. The references used for peak assignment are [41–45].
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
| (1) | 528 | S-S | Cancer | Phospholipids | Phosphatidylserine | <0.0001 | *** |
| (2) | 622 | C-C | Normal | Proteins | Phenylalanine | <0.0001 | *** |
| (3) | 657 | N – C | Normal | DNA/RNA | Adenine, Guanine | <0.0001 | *** |
| (4) | 881 | CH2 | Cancer | Proteins | Tryptophan, Proline, Valine | 0.0019 | ** |
| (5) | 712-24 | C-N | Normal | DNA/RNA, Proteins, Phospholipids | <0.0001 | *** | |
| (6) | 1068-77 | Cancer | DNA/RNA | Thymine | 0.00012 | *** | |
| (7) | 1243 | Amide III | Cancer | Proteins | <0.0001 | *** | |
| (8) | 1273 | C-H / C = CH | Cancer | Lipids | Unsaturated fatty acid | <0.0001 | *** |
| (9) | 1301 | CH2 / C-H | Cancer | Lipids | Triglycerides | 0.00025 | *** |
| (10) | 1337 | CH3 CH2 | Cancer | DNA/RNA, Proteins | Collagen | 0.022 | * |
| (11) | 1396 | CH2 | Normal | Lipids | <0.0001 | *** | |
| (12) | 1449 | C-H / CH2 | Cancer | Lipids, Proteins | Collagen | <0.0001 | *** |
| (13) | 1604 | C = C | Cancer | Proteins | Tyrosine, Tryptophan | <0.0001 | *** |
| (14) | 1630 | C = C / Amide I | Cancer | Proteins, Lipids | Lipids (lipid droplets) | <0.0001 | *** |
| (15) | 2878 | CH2 | Cancer | Lipids | <0.0001 | *** | |
| (16) | 2931 | CH2 / CH3 | Cancer | Proteins | <0.0001 | *** | |
Table summarizing accuracy, sensitivity, specificity and area under the ROC curve (AUC) for each test. The correspondent ROC curves are plotted in Fig. 3.
|
| ||||
|---|---|---|---|---|
|
|
|
|
| |
|
| 90 | 74 | 93 | 0.86 |
|
| 87 | 80 | 88 | 0.89 |
|
| 88 | 85 | 89 | 0.91 |
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
| 85 | 64 | 89 | 0.81 |
|
| 87 | 76 | 89 | 0.86 |
|
| 88 | 81 | 90 | 0.91 |
Fig. 3Receiver operating characteristic (ROC) curves showing the performance of classifications performed on fingerprint (FP) spectra, high wavenumber (HWN) spectra or FP + HWN spectra and using support vector machines (SVMs) and either leave-one-out cross-validation (LOOCV) or leave-one-patient-out cross-validation (LOPOCV). (a) ROC for HWN / FP / FP + HWN with LOOCV and LOPOCV. (b) Comparison of LOOCV/LOPOCV for HWN, FP and FP + HWN.